Literature DB >> 21417776

Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion.

Robertino M Mera1, Jose A Suaya, Heather Amrine-Madsen, Cosmina S Hogea, Linda A Miller, Emily P Lu, Daniel F Sahm, Patrick O'Hara, Camilo J Acosta.   

Abstract

BACKGROUND: There is the need to properly characterize the temporal trend of U.S. Staphylococcus aureus infections, including methicillin-resistant S. aureus (MRSA) and community-acquired (CA) MRSA in inpatient and outpatient settings.
METHODS: The study used the Surveillance Network(®) surveillance database (Eurofins Medinet) and the National Hospitalization Discharge Survey for the period 1998-2007. CA-MRSA phenotype was defined by a resistance profile that includes susceptibility to gentamicin and cotrimoxazole, and coresistance to ciprofloxacin/clindamycin. Adjusted rates, rate ratios, and 95% confidence intervals (CIs) were computed using multivariate logistic regression.
RESULTS: The study consisted of 1,761,991 S. aureus isolates. Annual MRSA prevalence continuously increased over the 10-year period from 32.7% in 1998 to 53.8% in 2007 (odds ratio 2.4, 95% CI 2.3-2.5). CA-MRSA replaced competing strains by increasing its share of MRSA from 22.3% in 1998 to 66.1% in 2007 (odds ratio 6.7, 95% CI 6.5-6.9). MRSA-related hospitalization rate per 1,000 discharges doubled from 3.5 ± 0.9 in 1998 to 7.6 ± 1.5 in 2007 (RR 2.2, 95% CI 1.8-3.1), whereas CA-MRSA increased from 0.4 ± 0.14 hospitalizations per 1,000 discharges in 1998 to 3.1 ± 0.5 in 2007 (RR 8.1, 95% CI 5.2-14.1), By 2007, 81.5% of all MRSA isolates were categorized as CA-MRSA among children, whereas CA-MRSA represented 48.9% of MRSA isolates from the elderly.
CONCLUSION: MRSA not only replaced methicillin susceptible S. aureus (MSSA) isolates as a percentage of all S. aureus isolates, but its hospitalization rates increased over and above the replacement process. This trend also applies to CA-MRSA over hospital-acquired (HA) MRSA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21417776     DOI: 10.1089/mdr.2010.0193

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  39 in total

1.  Antibiotic reduction campaigns do not necessarily decrease bacterial resistance: the example of methicillin-resistant Staphylococcus aureus.

Authors:  Lidia Kardas-Sloma; Pierre-Yves Boëlle; Lulla Opatowski; Didier Guillemot; Laura Temime
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

2.  Acquisition of the Phosphate Transporter NptA Enhances Staphylococcus aureus Pathogenesis by Improving Phosphate Uptake in Divergent Environments.

Authors:  Jessica L Kelliher; Jana N Radin; Kyle P Grim; Paola K Párraga Solórzano; Patrick H Degnan; Thomas E Kehl-Fie
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

3.  Infections caused by multidrug resistant organisms are not associated with overall, all-cause mortality in the surgical intensive care unit: the 20,000 foot view.

Authors:  Laura H Rosenberger; Damien J LaPar; Robert G Sawyer
Journal:  J Am Coll Surg       Date:  2012-03-13       Impact factor: 6.113

4.  Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; Davida S Smyth; Bo Shopsin; David J Farrell; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

5.  Impact of a surveillance screening program on rates of methicillin-resistant Staphylococcus aureus infections with a comparison of surgical versus nonsurgical patients.

Authors:  Andrew Jennings; Monica Bennett; Tammy Fisher; Alan Cook
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-04

6.  PhoPR Contributes to Staphylococcus aureus Growth during Phosphate Starvation and Pathogenesis in an Environment-Specific Manner.

Authors:  Jessica L Kelliher; Jana N Radin; Thomas E Kehl-Fie
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

7.  Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model.

Authors:  Jamese J Hilliard; Vivekananda Datta; Christine Tkaczyk; Melissa Hamilton; Agnieszka Sadowska; Omari Jones-Nelson; Terrence O'Day; William J Weiss; Szabolcs Szarka; Vien Nguyen; Laszlo Prokai; JoAnn Suzich; C Kendall Stover; Bret R Sellman
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

8.  Comparison of antibiograms developed for inpatients and primary care outpatients.

Authors:  Jessina C McGregor; David T Bearden; John M Townes; Susan E Sharp; Paul N Gorman; Miriam R Elman; Motomi Mori; David H Smith
Journal:  Diagn Microbiol Infect Dis       Date:  2013-03-27       Impact factor: 2.803

9.  Staphylococcal enterotoxin P predicts bacteremia in hospitalized patients colonized with methicillin-resistant Staphylococcus aureus.

Authors:  Michael S Calderwood; Christopher A Desjardins; George Sakoulas; Robert Nicol; Andrea Dubois; Mary L Delaney; Ken Kleinman; Lisa A Cosimi; Michael Feldgarden; Andrew B Onderdonk; Bruce W Birren; Richard Platt; Susan S Huang
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

10.  Methicillin-resistant Staphylococcus aureus colonization among medical residents.

Authors:  Pascale Trépanier; Claude Tremblay; Annie Ruest
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.